Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MediPharm Labs ( (TSE:LABS) ) has issued an update.
MediPharm Labs has signed a definitive supply agreement with Remidose Aerosols’ Costa Rican affiliate, Remidose LATAM, to export a portfolio of GMP-certified medicinal cannabis products—including oils, tinctures, metered dose inhalers and dried flower—into Costa Rica’s newly opened medical cannabis market. The deal positions MediPharm to tap into a regulated market projected to exceed US$35 million annually, reinforcing its strategy of leveraging its regulatory expertise and pharmaceutical-grade production standards to expand in highly controlled international jurisdictions while enabling Remidose LATAM to offer Costa Rican patients access to globally sourced, high-quality cannabis therapies.
The most recent analyst rating on (TSE:LABS) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on MediPharm Labs stock, see the TSE:LABS Stock Forecast page.
Spark’s Take on TSE:LABS Stock
According to Spark, TipRanks’ AI Analyst, TSE:LABS is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flow issues. Technical analysis indicates a bearish trend, and valuation metrics reflect ongoing losses, resulting in a lower score.
To see Spark’s full report on TSE:LABS stock, click here.
More about MediPharm Labs
MediPharm Labs, founded in 2015, is a pharmaceutical company specializing in precision-based cannabinoids and the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products. Operating from a GMP-certified facility with ISO-standard clean rooms, it supplies formulated, packaged and distributed cannabis and cannabinoid-based medicines to regulated domestic and international medical markets, underpinned by a Health Canada Pharmaceutical Drug Establishment License and expanded patient reach in Canada, Australia and Germany through its acquisition of VIVO Cannabis and associated medical platforms and clinics.
Average Trading Volume: 385,920
Technical Sentiment Signal: Hold
Current Market Cap: C$29.45M
For a thorough assessment of LABS stock, go to TipRanks’ Stock Analysis page.